UK Viral Vectors Plasmid DNA Manufacturing Market

ID: MRFR/HC/50125-HCR
200 Pages
Rahul Gotadki
Last Updated: February 06, 2026
UK Viral Vectors and Plasmid DNA Manufacturing Market Research Report: Size, Share, Trend Analysis By Vector Type (Plasmid DNA, Viral Vector, Non-viral Vector), By Disease Type (Cancer, Genetic Disorder, Infectious Disease), By Applications (Antisense & RNAi Therapy, Gene Therapy, Cell Therapy, Vaccinology, Research), By Workflow (Upstream Processing, Downstream Processing) and By End-User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Application (USD Million)
      1. 4.1.1 Gene Therapy
      2. 4.1.2 Vaccines
      3. 4.1.3 Oncology
      4. 4.1.4 Infectious Diseases
      5. 4.1.5 Genetic Disorders
    2. 4.2 Healthcare, BY End Use (USD Million)
      1. 4.2.1 Pharmaceutical Companies
      2. 4.2.2 Biotechnology Firms
      3. 4.2.3 Research Institutions
      4. 4.2.4 Academic Organizations
    3. 4.3 Healthcare, BY Type of Vector (USD Million)
      1. 4.3.1 Adenoviral Vectors
      2. 4.3.2 Lentiviral Vectors
      3. 4.3.3 Adeno-Associated Viral Vectors
      4. 4.3.4 Retroviral Vectors
    4. 4.4 Healthcare, BY Production Method (USD Million)
      1. 4.4.1 Transient Transfection
      2. 4.4.2 Stable Cell Line Development
      3. 4.4.3 Viral Packaging
      4. 4.4.4 Plasmid Preparation
    5. 4.5 Healthcare, BY Scale of Production (USD Million)
      1. 4.5.1 Small Scale
      2. 4.5.2 Medium Scale
      3. 4.5.3 Large Scale
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Oxford Biomedica (GB)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Cobra Biologics (GB)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Viralgen (GB)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Fujifilm Diosynth Biotechnologies (GB)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Lonza (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Genomatix (GB)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Aldevron (GB)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Wuxi AppTec (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY APPLICATION
    3. 6.3 UK MARKET ANALYSIS BY END USE
    4. 6.4 UK MARKET ANALYSIS BY TYPE OF VECTOR
    5. 6.5 UK MARKET ANALYSIS BY PRODUCTION METHOD
    6. 6.6 UK MARKET ANALYSIS BY SCALE OF PRODUCTION
    7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
    8. 6.8 RESEARCH PROCESS OF MRFR
    9. 6.9 DRO ANALYSIS OF HEALTHCARE
    10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
    13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
    15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
    16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 HEALTHCARE, BY TYPE OF VECTOR, 2024 (% SHARE)
    18. 6.18 HEALTHCARE, BY TYPE OF VECTOR, 2024 TO 2035 (USD Million)
    19. 6.19 HEALTHCARE, BY PRODUCTION METHOD, 2024 (% SHARE)
    20. 6.20 HEALTHCARE, BY PRODUCTION METHOD, 2024 TO 2035 (USD Million)
    21. 6.21 HEALTHCARE, BY SCALE OF PRODUCTION, 2024 (% SHARE)
    22. 6.22 HEALTHCARE, BY SCALE OF PRODUCTION, 2024 TO 2035 (USD Million)
    23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2026-2035 (USD Million)
      2. 7.2.2 BY END USE, 2026-2035 (USD Million)
      3. 7.2.3 BY TYPE OF VECTOR, 2026-2035 (USD Million)
      4. 7.2.4 BY PRODUCTION METHOD, 2026-2035 (USD Million)
      5. 7.2.5 BY SCALE OF PRODUCTION, 2026-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK UK Viral Vectors Plasmid DNA Manufacturing Market Segmentation

UK Viral Vectors Plasmid DNA Manufacturing Market By Application (USD Million, 2026-2035)

  • Gene Therapy
  • Vaccines
  • Oncology
  • Infectious Diseases
  • Genetic Disorders

UK Viral Vectors Plasmid DNA Manufacturing Market By End Use (USD Million, 2026-2035)

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Research Institutions
  • Academic Organizations

UK Viral Vectors Plasmid DNA Manufacturing Market By Type of Vector (USD Million, 2026-2035)

  • Adenoviral Vectors
  • Lentiviral Vectors
  • Adeno-Associated Viral Vectors
  • Retroviral Vectors

UK Viral Vectors Plasmid DNA Manufacturing Market By Production Method (USD Million, 2026-2035)

  • Transient Transfection
  • Stable Cell Line Development
  • Viral Packaging
  • Plasmid Preparation

UK Viral Vectors Plasmid DNA Manufacturing Market By Scale of Production (USD Million, 2026-2035)

  • Small Scale
  • Medium Scale
  • Large Scale

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035